Welcome to our dedicated page for Ir-Med news (Ticker: IRME), a resource for investors and traders seeking the latest updates and insights on Ir-Med stock.
IR-MED Inc. develops non-invasive, AI-powered infrared spectrographic medical-device technology for clinical decision support. Company news centers on its platform for assessing tissue, skin and blood-related biomarkers beneath the surface, with recurring updates on PressureSafe™ for pressure injury assessment and DiaSafe™ for diabetic foot ulcer assessment.
Coverage also includes clinical studies and presentations, collaborations with healthcare institutions, grants supporting product development, shareholder updates, financing needs, intellectual-property references and leadership or governance changes. PressureSafe™ is described by the company as a handheld, skin-color-agnostic decision support device for assessing pressure injuries before visible skin breakdown.
IR-MED, operating as a development stage medical device company, has signed a study agreement with Beit Rivka, a prominent Geriatric Hospital in Israel. This collaboration will focus on a usability study for their innovative device, PressureSafe, designed to aid in the early detection of pressure injuries (PI). This device utilizes AI technologies for real-time monitoring, targeting a significant health issue faced by care providers. The annual cost related to hospital-acquired pressure injuries in the US exceeds $26.8 billion, underlining the importance of preventative measures in healthcare facilities.
IR-MED has appointed Moshe Gerber as the new Chief Executive Officer, effective immediately. Mr. Gerber brings over 25 years of experience in international business development, particularly in the medical device sector. He previously founded Gerium Medical, which developed jaundice measurement devices, and later sold it to Mennen Medical. His focus on innovation and growth positions IR-MED favorably as they develop non-invasive detection technologies. The company is pioneering a optical monitoring device aimed at early detection of pressure injuries.
IR-Med, a medical device company, announced a Subscription Agreement for the sale of 3,636,364 shares at $0.88 per share and warrants for another 3,636,364 shares at $1.10 each, resulting in gross proceeds of $3,200,000. CEO Dr. Rom Eliaz stated that this funding strengthens their balance sheet and facilitates future developments. The proceeds will support general corporate purposes and product development. The company is focused on non-invasive technology for real-time blood and tissue analysis, targeting early detection of pressure injuries.
IR-Med has announced its approval to up-list from Pink Sheets to the OTCQB tier, effective February 1, 2022. This transition reflects the company’s compliance with enhanced financial reporting and transparency standards required by the OTCQB marketplace. CEO Dr. Rom Eliaz emphasized that this listing will bolster investor awareness and support the company’s growth strategy. IR-Med is focused on developing non-invasive spectral analysis technology for healthcare applications, including monitoring pressure injuries.
IR-Med (OTC: IRME) announced key corporate updates, including plans to initiate usability testing of its 'PressureSafe' device and apply for FDA premarket submission in H1 2022. With IRB-Helsinki approval from Beit Rivka hospital, the company aims for market entry in the US by Q4 2022. Additionally, IR-Med has applied for OTCQB up-listing, supported by audited financials compliant with US GAAP. The company has also engaged Dolos Consultancy for investor relations and market intelligence services. CEO Dr. Rom Eliaz highlighted progress amid pandemic challenges, asserting confidence in the company's strategic goals.
IR-Med, Inc. (OTCPINK: IRME) is poised for a transformative year in 2022 after overcoming challenges during the COVID-19 pandemic. The company focuses on developing non-invasive optical diagnostic devices, specifically PressureSafe, aimed at early detection of pressure injuries. Key milestones include proof of concept results and filing for FDA clearance in H1 2022, with production targeted for late 2022, contingent on regulatory approval. Additionally, IR-Med is enhancing visibility for investors and pursuing business development opportunities in healthcare.
IR-Med, Inc. (OTCPINK: IRME) announced its application to uplist to the OTCQB and the SEC's declaration of its resale Registration Statement on Form S-1 effective November 9, 2021. The Registration Statement includes approximately 38 million shares, with 9 million available upon exercise at $0.64 per share. Importantly, IR-Med is not selling securities and will not receive proceeds from any sales. The company has met the OTCQB market's compliance requirements and aims to enhance visibility and access to capital markets.
IR-Med, Inc. (OTCPINK: IRME) has appointed Dr. Rom Eliaz as its new Chief Executive Officer. Dr. Eliaz brings extensive experience from roles including Founder of Elrom Ventures and Head of Merck Ventures’ Fund in Israel. His background includes leadership positions at Teva and NasVax. The company aims to leverage his expertise to enhance its development of sensor-based medical devices targeting chronic conditions. Dr. Eliaz expressed enthusiasm for the opportunity to lead IR-Med in modernizing healthcare solutions.
IR-Med, Inc. (OTCPink: IRME) announced the resignation of CEO Limor Davidson Mund due to personal reasons. Mr. Oded Bashan, the current Chairman, is appointed as interim CEO. IR-Med is a development stage company focused on utilizing Infra-Red and Artificial Intelligence technologies for early detection of medical conditions such as pressure injuries and ear infections in children. This management change could provide new leadership perspectives as the company continues its development in the healthcare sector.